Projects per year
Fingerprint
Dive into the research topics where Yvonne M. Saenger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Applying pathomics to establish a biosignature for aggressive skin melanoma
Saenger, Y. M. (PI), Chang, R. R. (CoPI) & Chang, R. (CoPI)
5/1/21 → 4/30/25
Project: Research project
-
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx
Verma, A. K. (PI) & Saenger, Y. M. (CoPI)
4/1/23 → 3/31/24
Project: Research project
-
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx
Verma, A. A. K. (PI) & Saenger, Y. M. (CoPI)
4/1/23 → 3/31/24
Project: Research project
-
A prognostic mRNA immune signature for resected stage II-III melanoma
Saenger, Y. M. (PI)
4/1/22 → 3/31/23
Project: Research project
-
A prognostic mRNA immune signature for resected stage II-III melanoma
Saenger, Y. M. (PI) & Krolewski, J. J. (CoPI)
4/1/22 → 3/31/24
Project: Research project
-
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation
Mendelson, K., Martin, T. C., Nguyen, C. B., Hsu, M., Xu, J., Lang, C., Dummer, R., Saenger, Y., Messina, J. L., Sondak, V. K., Desman, G., Hasson, D., Bernstein, E., Parsons, R. E. & Celebi, J. T., 2024, In: JCI Insight. 9, 6, e166611.Research output: Contribution to journal › Article › peer-review
Open Access -
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients
Ko, B., Tao, K., Brennan, L., Rakhade, S., Chan, C. X., Moone, J. Y., Zhu, R., Sher, A., Wang, S., Bracero, Y., Fullerton, B., McLellan, B., Geskin, L. J. & Saenger, Y. M., Apr 1 2024, In: Melanoma Research. 34, 2, p. 134-141 8 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Yarchoan, M., Powderly, J. D., Bastos, B. R., Karasic, T. B., Crysler, O. V., Munster, P. N., McKean, M. A., Emens, L. A., Saenger, Y. M., Ged, Y., Stagg, R., Smith, S., Whiting, C. C., Moon, A., Prasit, P., Jenkins, Y., Standifer, N., Dubensky, T. W., Whiting, S. H. & Ulahannan, S. V., Apr 2024, In: Cancer research communications. 4, 4, p. 1100-1110 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States
Bteich, F., Desai, K., Zhang, C., Kaur, A., Levy, R. A., Bioh, L., Wang, A., Sultana, S., Kaubisch, A., Kinkhabwala, M., Bellemare, S., Fidvi, S., Kanmaniraja, D., Berkenblit, R., Moon, J. Y., Adedimeji, A., Tow, C. Y. & Saenger, Y., 2024, In: Journal of Hepatocellular Carcinoma. 11, p. 257-269 13 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
An update on methods for detection of prognostic and predictive biomarkers in melanoma
Adeuyan, O., Gordon, E. R., Kenchappa, D., Bracero, Y., Singh, A., Espinoza, G., Geskin, L. J. & Saenger, Y. M., 2023, In: Frontiers in Cell and Developmental Biology. 11, 1290696.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations